Unlocking The Potential of LINC00301: A Non-Coding RNA Molecule as A Drug Target and Biomarker

Target Name: LINC00301

NCBI ID: G283197

LINC00301

Other Name(s): C11orf64 | long intergenic non-protein coding RNA 301 | Long intergenic non-protein coding RNA 301 | NCRNA00301

Unlocking The Potential of LINC00301: A Non-Coding RNA Molecule as A Drug Target and Biomarker

LINC00301 (C11orf64) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biochemical properties make it an attractive target for researchers to study and develop new treatments.

The LINC00301 molecule is composed of 21 amino acid residues and has a molecular weight of 23.9 kDa. It is characterized by a stem-loop structure that is composed of a central alpha-helic acid loop and two 3'-terminal exons. The loop region has a pectin loop that is responsible for the molecule's stability and can interact with various proteins, which may play a role in its function.

One of the most significant features of LINC00301 is its ability to self-cleave, which means it can break down into smaller pieces on its own. This property is known as \"self-cleavage\" and is a unique feature of RNA molecules. The self-cleavage mechanism allows the molecule to interact with various proteins and molecules, which may be involved in its function.

In addition to its self-cleavage property, LINC00301 has been shown to interact with several proteins that are involved in various cellular processes, including cell signaling, cell division, and apoptosis. One of the most interesting of these interactions is its interaction with the protein p53, which is a well-known tumor suppressor protein that is involved in regulating various cellular processes, including DNA replication, apoptosis, and cell growth.

Research has also shown that LINC00301 can interact with the proteinINK4a, which is a key regulator of the insulin/IGF-1 signaling pathway. This interaction may be involved in the regulation of cellular processes that are related to insulin sensitivity and metabolism.

Another interesting aspect of LINC00301 is its ability to interact with the protein TAS104, which is a known regulator of the T-cell receptor signaling pathway. This interaction may be involved in the regulation of cellular processes that are related to immune function and may have implications for the development of cancer.

In addition to its interactions with these proteins, LINC00301 has also been shown to interact with several other molecules, including the protein asparagus bean protein (ASP) and the protein UZF1A. These interactions may be involved in the regulation of various cellular processes, including cell signaling, cell division, and apoptosis.

The potential drug target and biomarker properties of LINC00301 are based on its unique structure and biochemical properties, as well as its ability to interact with various proteins that are involved in various cellular processes. Further research is needed to fully understand the function of this molecule and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 301

The "LINC00301 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00301 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets